Close Menu

NEW YORK ─ Massachusetts Institute of Technology spinout Glympse Bio said on Wednesday that it has closed an oversubscribed $46.7 million Series B financing round.

The Cambridge, Massachusetts-based firm said it anticipates using the proceeds to support the continued development of its biosensor platform for the diagnosis of cancers, infectious diseases, and fibrotic diseases such as non-alcoholic steatohepatitis (NASH).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.